Genelux Corporation (GNLX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Genelux Corporation (GNLX) closed at USD 2.32 on 2026-10-14, a change of -69.6 % over the past year, with a market capitalization of USD 112.21M.

Genelux Corporation recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Genelux Corporation key figures

Previous close

USD 2.32 (2026-10-14)

1-year change

-69.6 %

Market cap

USD 112.21M

Enterprise value

USD 94.88M

P/E ratio (trailing)

-2.92

P/E ratio (forward)

-3.30

EPS (trailing)

-0.85

EPS (forward)

-0.75

PEG ratio

n/a

Price to book

6.87

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

17.24

Employees

25

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Genelux Corporation

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Genelux Corporation and compare it with other stocks.